The Galleri Test in Arizona: What a Multi-Cancer Blood Test Can and Cannot Tell You
Medically reviewed by Dr. Mia Chorney, DNP, FNP-BC, MSCP — Cofounder & Chief Medical Officer, Amsara Health
Updated September 23, 2026: An FDA advisory panel voted in favor of approving Galleri. Read what the vote means.
If you have heard about a single blood draw that screens for more than fifty cancers, you have heard about the Galleri® test. It is real, it is available in Arizona, and it is one of the more consequential tools to arrive in preventive medicine in a generation. It is also widely misunderstood, in both directions: oversold by some who market it, and dismissed by others who have not read the 2026 data. This is the clinical picture as it stands today, including what the test cannot do.
What does the Galleri test actually measure?
Galleri, made by GRAIL, looks for cell-free DNA that tumors shed into the bloodstream. Rather than searching for mutations, it reads methylation patterns, the chemical marks that tell a cell which genes to switch on or off. Cancer cells carry characteristic methylation signatures, and those signatures also point to the likely tissue of origin. A single result therefore answers two questions: is a cancer signal present, and if so, where is it most likely coming from? GRAIL reports that the test predicted the correct tissue of origin more than 90 percent of the time in its most recent study.
It is not a diagnostic test. A “Cancer Signal Detected” result is the beginning of a workup, not a diagnosis, and the confirmation still comes from imaging and biopsy. That distinction matters more than any other fact in this article.
How accurate is the Galleri test? The FDA’s numbers
In September 2026 the FDA published its own independent analysis of the two largest Galleri studies in its briefing document for the advisory panel. We use the FDA’s figures because they are the numbers the panel voted on.
PATHFINDER 2 enrolled more than 35,000 adults aged 50 and older in the United States; the FDA analyzed 22,698 participants with twelve months of follow-up. Specificity was 99.85 percent, meaning fewer than two false alarms per 1,000 people without cancer. When the test flagged a cancer signal, it was right 77 percent of the time, and it pointed to the correct organ system 94.3 percent of the time. Over twelve months it detected 35 percent of the cancers diagnosed, including about one in four stage I and II cancers.
The NHS-Galleri trial in England was the harder test: a randomized controlled trial of 142,250 people aged 50 to 77 across three annual screening rounds. The FDA reported 99.74 percent specificity, a 66.2 percent positive predictive value, 91.9 percent accuracy in locating a cancer’s origin, and 31.6 percent of cancers detected within a year. The trial’s primary goal, a statistically significant reduction in stage III and IV cancers, was not met, although stage IV diagnoses fell by the third annual round. In plain terms, the test finds some cancers earlier, especially with repeated annual use, but no trial has yet shown that it reduces cancer deaths.
An honest summary: Galleri is highly specific, moderately sensitive, considerably better at catching aggressive cancers than slow ones, and unproven on the outcome that ultimately matters. Independent commentators continue to raise fair questions about overdiagnosis and lead-time bias, and we think patients deserve to hear them.
Is Galleri FDA approved?
Not yet, but it moved much closer on September 23, 2026. That day, the FDA’s Molecular and Clinical Genetics Devices Panel voted in favor of GRAIL’s premarket approval application for screening adults aged 50 and older: unanimous on safety, 6 to 4 on effectiveness, and 7 to 2 (with one abstention) that the benefits outweigh the risks. The FDA makes the final decision, which GRAIL expects in the coming months. Until then, Galleri remains a laboratory-developed test run in GRAIL’s CLIA-certified laboratory, a legal and common pathway for advanced diagnostics. Read our full breakdown of the FDA panel vote.
Separately, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was signed into law in February 2026. It gives Medicare the authority to cover tests like Galleri once they are FDA approved and have demonstrated clinical benefit. It does not create coverage today.
Does Galleri replace my mammogram, colonoscopy, or other screenings?
No, and GRAIL says so on its own label. Mammography, colonoscopy, cervical screening, and low-dose CT for eligible smokers each have decades of evidence that they reduce deaths from the cancers they target. Galleri does not have that evidence yet, and it misses a meaningful share of early-stage cancers. The correct framing is the one the American Academy of Family Physicians uses: a possible complement to guideline screening, never a substitute. At Amsara, we do not order Galleri for a patient who is behind on standard screening without first closing that gap.
What happens if my result says “Cancer Signal Detected”?
Your provider becomes very important. Roughly 40 percent of positive signals in the recent studies turned out not to be cancer, so the first job is to say that plainly and calmly. The second is to use the predicted tissue of origin to choose targeted imaging, usually a CT or PET-CT, sometimes a scope or a specialist referral, and to move quickly. In PATHFINDER 2 the median time from signal to a definitive answer was 48 days. Follow-up imaging is billed separately and may or may not be covered by your insurance; GRAIL offers patient advocates who help with that process, and so do we.
A negative result deserves equal honesty. “No Cancer Signal Detected” lowers the probability of an active cancer; it does not eliminate it. Keep every routine screening on schedule.
Who is Galleri for, and who should not take it?
GRAIL recommends the test for adults with an elevated risk of cancer, such as those aged 50 or older, and it is the population in which every large study has been run. It is not recommended during pregnancy, under age 22, or during active cancer treatment. Between 40 and 50, the case is individual: a strong family history, prior radiation exposure, or genetic risk factors can justify it, and those are exactly the conversations a longer appointment is for. This is why every Amsara test is ordered and reviewed by your provider rather than sold off a menu.
How do I get the Galleri test in Arizona, and what does it cost?
Galleri requires an order from a licensed clinician. At Amsara Health the blood is drawn at a Sonora Quest location near you, results return in roughly two weeks, and your provider reviews them with you at a follow-up visit, with a plan already in hand if the result requires one. GRAIL’s national list price is $949; it is not covered by Medicare or most insurers today, though HSA and FSA funds may often be applied to the test itself. Current Amsara pricing, including our member rate and a limited-time Arizona offer through October 31, 2026, is on our Tests & Services page. Members receive 20 percent off all non-insurable testing as part of membership.
Where does Galleri fit in a longevity plan?
On its own, a cancer screen is a snapshot. Inside a plan, it becomes a habit: the NHS-Galleri data suggest the benefit grows with each annual round, which is exactly how we use it, alongside biological age testing, comprehensive metabolic panels, and the unglamorous fundamentals that lower cancer risk in the first place. If you are weighing whether it is right for you, start with a conversation with someone who will give you the numbers above rather than a brochure. That is the whole point of how Amsara was built.
Frequently asked questions
Does the Galleri test replace a mammogram or colonoscopy?
No. Galleri is designed to complement guideline-recommended screenings, not replace them. Mammography, colonoscopy, cervical screening, and lung CT have proven mortality benefits that Galleri does not yet have. Stay current on standard screening whether or not you take Galleri.
Is Galleri FDA approved in 2026?
Not yet. On September 23, 2026, an FDA advisory panel voted in favor of approval, 7 to 2 on benefit versus risk, and a final FDA decision is expected in the coming months. Until then it is offered as a laboratory-developed test from a CLIA-certified lab.
If Galleri detects a cancer signal, how likely is it that I have cancer?
In the FDA analysis of the PATHFINDER 2 study, 77 percent of people with a cancer signal were confirmed to have cancer, which means roughly 1 in 4 were false positives. In the NHS-Galleri trial the figure was 66 percent. Confirmation requires follow-up imaging and sometimes biopsy, which your provider coordinates.
Can a negative Galleri result mean I definitely do not have cancer?
No. In the NHS-Galleri trial the test detected about 55 percent of the twelve deadliest cancers and about 31 percent of all cancers diagnosed within a year. A negative result lowers the likelihood of cancer but does not rule it out.
Where can I get the Galleri test in Arizona?
Galleri requires a clinician’s order. Amsara Health orders the test for appropriate patients, with the blood draw at a Sonora Quest location in Arizona and results reviewed at a telehealth follow-up visit.
How much does Galleri cost, and does insurance pay for it?
GRAIL’s list price is $949. Medicare and most insurers do not cover it today, though the 2026 Medicare MCED law allows coverage after FDA approval. HSA or FSA funds may often be used. Amsara’s current pricing and member rate are on the Tests & Services page.
Who should not take the Galleri test?
It is not recommended for people who are pregnant, under 22, or in active cancer treatment, and it has been studied mainly in adults 50 and older. Adults in their forties with elevated risk should discuss it individually with a provider.
How often should Galleri be repeated?
The NHS-Galleri trial found the reduction in late-stage diagnoses grew with each of three annual rounds, so annual testing is the pattern the evidence supports for people who choose to use it.
This article is for education only and is not medical advice. Talk with a qualified clinician about your individual health before starting or stopping any therapy.
Wondering whether Galleri belongs in your plan?
Unhurried appointments, advanced diagnostics, and a plan built for you.
Already a patient? Visit your Amsara Patient Portal →
